AERIE PHARMACEUTICALS INC Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017
Cash flows from operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation
Amortization of debt issuance costs and fees
Amortization and accretion of premium or discount on investments, net
Amortization and accretion
Acquisition of assets expensed to research and development
Stock-based compensation
Unrealized foreign exchange loss
Induced conversion of 2014 Convertible Notes
Other non-cash

Changes in operating assets and liabilities
Accounts receivable, net
Inventory
Prepaid, current and other assets
Licensing receivable
Accounts payable, accrued expenses and other current liabilities
Operating lease liabilities
Deferred revenue
Net cash used in operating activities
Cash flows from investing activities
Acquisition of assets
Purchase of available-for-sale investments
Proceeds from sales and maturities of investments
Purchase of property, plant and equipment
Net cash (used in) provided by investing activities
Cash flows from financing activities
Proceeds from loan
Repayment of loan
Proceeds from sale of common stock, net
Proceeds related to issuance of stock for stock-based compensation arrangements, net
Proceeds related to issuance of common stock for stock-based compensation arrangements, net
Proceeds from exercise of warrants
Proceeds from convertible notes, net of issuance costs
Payments of issuance costs
Payment for capped call options
Other financing
Net cash provided by (used in) financing activities

Net change in cash and cash equivalents
Cash and cash equivalents, at beginning of period
Cash and cash equivalents, at end of period
Supplemental disclosures
Cash paid for interest
Cash paid for income taxes
Non-cash investing and financing activities:
Conversion of convertible notes to common stock (Note 10)
Equity issued for Envisia Asset Acquisition
Envisia Therapeutics Inc.
Total equity issued for Envisia Asset Acquisition

Liabilities incurred from Avizorex Asset Acquisition
Purchases of property, plant and equipment in accounts payable and accrued expense and other current liabilities
Acquisition of capital lease obligation
Deferred costs from the sale of common stock

Comments